HPV vaccine recommendations by age: A survey of providers in federally qualified health centers

References

• IARC. Cervical cancer screening IARC handbooks of cancer prevention volume 18. Published online 2022 [accessed 2022 Dec 23]. https://publications.iarc.fr/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-Prevention/Cervical-Cancer-Screening-2022.
   Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez‐avila M, Wheeler C, Perez G, Koutsky L, Tay E, Garcia P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 2009;199(7):926–9. doi:10.1086/597307.
   PubMed Web of Science ®Google Scholar
• Mix JM, Van Dyne EA, Saraiya M, Hallowell BD, Thomas CC. Assessing impact of HPV vaccination on cervical cancer incidence among women aged 15-29 years in the United States, 1999-2017: an ecologic study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2021;30(1):30–37. doi:10.1158/1055-9965.EPI-20-0846.
   Google Scholar
• Brisson M, Bénard É, Drolet M, Bogaards JA, Baussano I, Vänskä S, Jit M, Boily M-C, Smith MA, Berkhof J, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8–17. doi:10.1016/S2468-2667(16)30001-9.
   PubMed Web of Science ®Google Scholar
• Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, Sundström K, Dillner J, Sparén P. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340–48. doi:10.1056/NEJMoa1917338.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Bryant A, Beutels P, PPL Martin-Hirsch, E Paraskevaidis, E Van Hoof, M Steben, Y Qiao, FH Zhao, A Schneider, A Kaufmann, J Dillner, L Markowitz, A Hildesheim. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2011;2011(4):CD009069. doi:10.1002/14651858.CD009069.
   PubMedGoogle Scholar
• Kjaer SK, Nygård M, Dillner J, Brooke Marshall J, Radley D, Li M, Munk C, Hansen BT, Sigurdardottir LG, Hortlund M, et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries. Clin Infect Dis off Publ Infect Dis Soc Am. 2018;66(3):339–45. doi:10.1093/cid/cix797.
   PubMed Web of Science ®Google Scholar
• Porras C, Tsang SH, Herrero R, Guillén D, Darragh TM, Stoler MH, Hildesheim A, Wagner S, Boland J, Lowy DR, et al. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica vaccine trial. Lancet Oncol. 2020;21(12):1643–52. doi:10.1016/S1470-2045(20)30524-6.
   PubMed Web of Science ®Google Scholar
• Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, Elliss-Brookes L, Sasieni P. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet Lond Engl. 2021;398(10316):2084–92. doi:10.1016/S0140-6736(21)02178-4.
   PubMed Web of Science ®Google Scholar
• Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11(1):227. doi:10.1186/1741-7015-11-227.
   PubMed Web of Science ®Google Scholar
• Perkins RB, Lin M, Wallington SF, Hanchate A. Impact of number of human papillomavirus vaccine doses on genital warts diagnoses among a national cohort of U.S. adolescents. Sex Transm Dis. 2017;44(6):365–70. doi:10.1097/OLQ.0000000000000615.
   PubMed Web of Science ®Google Scholar
• Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M. Human papillomavirus-attributable cancers - United States, 2012-2016. MMWR Morb Mortal Wkly Rep. 2019;68(33):724–28. doi:10.15585/mmwr.mm6833a3.
   PubMed Web of Science ®Google Scholar
• Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, Steinau M, Watson M, Wilkinson EJ, Hopenhayn C, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6):djv086. doi:10.1093/jnci/djv086.
   PubMedGoogle Scholar
• ACIP. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2007;56. (No RR-2).
   Google Scholar
• ACIP. Recommendations on the use of quadrivalent human papillomavirus vaccine in males–Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011;60(50):1705–08.
   PubMedGoogle Scholar
• Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698–702. doi:10.15585/mmwr.mm6832a3.
   PubMed Web of Science ®Google Scholar
• Pingali C, Yankey D, Elam-Evans LD, Markowitz LE, Valier MR, Fredua B, Crowe SJ, Stokley S, Singleton JA. National vaccination coverage among adolescents aged 13–17 years — national immunization survey-teen, United States, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(35):1101–08. doi:10.15585/mmwr.mm7135a1.
   PubMed Web of Science ®Google Scholar
• Casey SM, Jansen E, Drainoni ML, Schuch TJ, Leschly KS, Perkins RB. Long-term multilevel intervention impact on human papillomavirus vaccination rates spanning the COVID-19 pandemic. J Low Genit Tract Dis. 2022;26(1):13–19. doi:10.1097/LGT.0000000000000648.
   PubMed Web of Science ®Google Scholar
• Perkins RB, Legler A, Jansen E, Bernstein J, Pierre-Joseph N, Eun TJ, Biancarelli DL, Schuch TJ, Leschly K, Fenton ATHR, et al. Improving HPV vaccination rates: a stepped-wedge randomized trial. Pediatrics. 2020;146(1). doi:10.1542/peds.2019-2737.
   PubMed Web of Science ®Google Scholar
• Goleman MJ, Dolce M, Morack J. Quality improvement initiative to improve human papillomavirus vaccine initiation at 9 years of age. Acad Pediatr. 2018;18(7):769–75. doi:10.1016/j.acap.2018.05.005.
   PubMed Web of Science ®Google Scholar
• St Sauver JL, Rutten LJF, Ebbert JO, Jacobson DJ, McGree ME, Jacobson RM. Younger age at initiation of the human papillomavirus (HPV) vaccination series is associated with higher rates of on-time completion. Prev Med. 2016;89:327–33. doi:10.1016/j.ypmed.2016.02.039.
   PubMed Web of Science ®Google Scholar
• Cox JE, Bogart LM, Elliott MN, Starmer AJ, Meleedy-Rey P, Goggin K, Banerjee T, Samuels RC, Hahn PD, Epee-Bounya A, et al. Improving HPV vaccination rates in a racially and ethnically diverse pediatric population. Pediatrics. 2022;150(4):e2021054186. doi:10.1542/peds.2021-054186.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on. Why AAP recommends initiating HPV vaccination as early as age 9. Published online 2019 [accessed 2022 Sep 28]. https://publications.aap.org/aapnews/news/14942?autologincheck=redirected?nfToken=00000000-0000-0000-0000-000000000000.
   Google Scholar
• American Cancer Society. ACS updates HPV vaccination recommendations to start at age 9. Published online 2020 [accessed 2022 Sep 28]. https://www.cancer.org/latest-news/acs-updates-hpv-vaccination-recommendations-to-start-at-age-9.html.
   Google Scholar
• Gilkey MB, McRee AL. Provider communication about HPV vaccination: a systematic review. Hum Vaccines Immunother. 2016;12(6):1454–68. doi:10.1080/21645515.2015.1129090.
   PubMed Web of Science ®Google Scholar
• Lin C, Mullen J, Smith D, Kotarba M, Kaplan SJ, Tu P. Healthcare providers’ vaccine perceptions, hesitancy, and recommendation to patients: a systematic review. Vaccines. 2021;9(7):713. doi:10.3390/vaccines9070713.
   Web of Science ®Google Scholar
• Kong WY, Bustamante G, Pallotto IK, Margolis MA, Carlson R, McRee A-L, Gilkey MB. Disparities in healthcare providers’ recommendation of HPV vaccination for U.S. adolescents: a systematic review. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2021;30(11):1981–92. doi:10.1158/1055-9965.EPI-21-0733.
   Google Scholar
• Constable C, Ferguson K, Nicholson J, Quinn GP. Clinician communication strategies associated with increased uptake of the human papillomavirus (HPV) vaccine: a systematic review. CA Cancer J Clin. 2022;72(6):561–69. doi:10.3322/caac.21753.
   PubMed Web of Science ®Google Scholar
• Biancarelli DL, Drainoni ML, Perkins RB. Provider experience recommending HPV vaccination before age 11 years. J Pediatr. Published online 2019 Nov 19;217:92–97. doi:10.1016/j.jpeds.2019.10.025.
   PubMed Web of Science ®Google Scholar
• Kong WY, Huang Q, Thompson P, Grabert BK, Brewer NT, Gilkey MB. Recommending human papillomavirus vaccination at age 9: a national survey of primary care professionals. Acad Pediatr. 2022;22(4):573–80. doi:10.1016/j.acap.2022.01.008.
   PubMed Web of Science ®Google Scholar
• Miller MJ, Xu L, Qin J, Hahn EE, Ngo-Metzger Q, Mittman B, Tewari D, Hodeib M, Wride P, Saraiya M, et al. Impact of COVID-19 on cervical cancer screening rates among women aged 21–65 years in a large integrated health care system — Southern California, January 1–September 30, 2019, and January 1–September 30, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(4):109–13. doi:10.15585/mmwr.mm7004a1.
   PubMed Web of Science ®Google Scholar
• Wentzensen N, Clarke MA, Perkins RB. Impact of COVID-19 on cervical cancer screening: challenges and opportunities to improving resilience and reduce disparities. Prev Med. 2021;151:106596. doi:10.1016/j.ypmed.2021.106596.
   PubMed Web of Science ®Google Scholar
• Brennan LP, Rodriguez NM, Head KJ, Zimet GD, Kasting ML. Obstetrician/Gynecologists’ HPV vaccination recommendations among women and girls 26 and younger. Prev Med Rep. 2022;27:101772. doi:10.1016/j.pmedr.2022.101772.
   PubMedGoogle Scholar
• Kempe A, O’leary ST, Markowitz LE, Crane LA, Hurley LP, Brtnikova M, Beaty BL, Meites E, Stokley S, Lindley MC. HPV vaccine delivery practices by primary care physicians. Pediatrics. 2019;144(4):e20191475. doi:10.1542/peds.2019-1475.
   PubMed Web of Science ®Google Scholar
• CDC. Vaccines for children program. Published 2012. http://www.cdc.gov/vaccines/programs/vfc/index.html.
   Google Scholar
• Fenton AT, Eun TJ, Clark JA, Perkins RB. Indicated or elective? The association of providers’ words with HPV vaccine receipt. Hum Vaccines Immunother. Published online 2018 May 30 ;1–7. doi:10.1080/21645515.2018.1480237.
   Web of Science ®Google Scholar
• Eun TJ, Hanchate A, Fenton AT, et al. Relative contributions of parental intention and provider recommendation style to HPV and meningococcal vaccine receipt. Hum Vaccines Immunother. Published online 2019 Mar 12;1–6. doi:10.1080/21645515.2019.1591138.
   Web of Science ®Google Scholar
• Gilkey MB, Calo WA, Moss JL, Shah PD, Marciniak MW, Brewer NT. Provider communication and HPV vaccination: the impact of recommendation quality. Vaccine. 2016;34(9):1187–92. doi:10.1016/j.vaccine.2016.01.023.
   PubMed Web of Science ®Google Scholar
• Vadaparampil ST, Malo TL, Kahn JA, Salmon DA, Lee J-H, Quinn GP, Roetzheim RG, Bruder KL, Proveaux TM, Zhao X, et al. Physicians’ human papillomavirus vaccine recommendations, 2009 and 2011. Am J Prev Med. 2014;46(1):80–84. doi:10.1016/j.amepre.2013.07.009.
   PubMed Web of Science ®Google Scholar
• Btoush R, Kohler RK, Carmody DP, Hudson SV, Tsui J. Factors that influence healthcare provider recommendation of HPV vaccination. Am J Health Promot AJHP. 2022;36(7):1152–61. doi:10.1177/08901171221091438.
   PubMed Web of Science ®Google Scholar
• Bynum SA, Staras SAS, Malo TL, Giuliano AR, Shenkman E, Vadaparampil ST. Factors associated with Medicaid providers’ recommendation of the HPV vaccine to low-income adolescent girls. J Adolesc Health off Publ Soc Adolesc Med. 2014;54(2):190–96. doi:10.1016/j.jadohealth.2013.08.006.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists’ Committee on Adolescent Health Care; and Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. Human papillomavirus vaccination: ACOG committee opinion, number 809. Obstet Gynecol. 2020;136(2):e15–21. doi:10.1097/AOG.0000000000004000.
   PubMed Web of Science ®Google Scholar
• Kashani BM, Tibbits M, Potter RC, Gofin R, Westman L, Watanabe-Galloway S. Human papillomavirus vaccination trends, barriers, and promotion methods among American Indian/Alaska Native and non-Hispanic white adolescents in Michigan 2006-2015. J Community Health. 2019;44(3):436–43. doi:10.1007/s10900-018-00615-4.
   PubMed Web of Science ®Google Scholar
• Chido-Amajuoyi OG, Talluri R, Wonodi C, Shete S. Trends in HPV vaccination initiation and completion within ages 9-12 years: 2008-2018. Pediatrics. 2021;147(6):e2020012765. doi:10.1542/peds.2020-012765.
   PubMed Web of Science ®Google Scholar